WiseNews app reports that Touyun Biotech (01332) announced that on September 30, 2024, the company implemented a stock repurchase program as of June 2, 2022, granting stock options to 7 directors, 30 employees, and 14 service providers to subscribe for a total of 0.279 billion shares of common stock with a face value of 0.04 Hong Kong dollars per share, subject to acceptance by the grantee. The exercise price for the stock options is HK$0.20 per share.